Bruns Ingmar
- SEC CIK
- 0001838041
In the past year, 1 open-market sale filing worth $8.00K and no purchases.
Current role at each company
- ZNTL Zentalis Pharmaceuticals, Inc.Chief Medical Officeras of Feb 10, 2026
- Trillium Therapeutics Inc.Chief Medical Officeras of Nov 19, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $8.00K
- 1 filing
- Net
- −$8.00K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Bruns Ingmar as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ZNTL Zentalis Pharmaceuticals, Inc.
Chief Medical Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 (view filing) | Feb 6-9 | 4 days | Bruns IngmarChief Medical Officer | SSale | −3.30K | $2.43 | −$8.00K | −9.0%33.3K after | 2 lots |
| Feb 12, 2025 (view filing) | Feb 6 | 6 daysLate | Bruns IngmarChief Medical Officer | PPurchase | +20.0K | $2.28 | +$45.6K | +120.3%36.6K after |